Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: Results from the PRESENT study

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 645-652

  Sharma, Surendra Kumar ^a,h   Al Mustafa, M ^b   Oh, S J ^c   Azar, S T ^d   Shestakova, M ^e   Guler, S ^f   Vaz, J A ^g  

^a MG Medical College Jaipur   (India)

^b National Diabetes Centre   (Iraq)

^c Kyung Hee University College of Medicine   (South Korea)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^e Institute of Diabetes   (Russian Federation)

^f ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g Novo Nordisk Pharma Singapore Pte Ltd   (Singapore)

^h NONE   (India)

Author keywords

Biphasic insulin aspart 30; HbA1c; Human insulin; Hypoglycaemia; Oral hypoglycaemic agents; Type 2 diabetes mellitus

Indexed keywords

BIPHASIC INSULIN ASPART 30; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 41149143684     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X260952     Document Type: Article

References (24)

1. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004;70:489-500 [published correction appears in Am Fam Physician 2004;70:2079-80]
2. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 1st edn. Brussels: International Diabetes Federation, 2005
3. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. AACE medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13 (Suppl 1):3-68
4. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next? Diabetes Metab Res Rev 2007;23:257-64
5. Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes Metab 2006;8:110-5
6. Dickinson PJ, Dornhorst A, Frost GS. A retrospective case-control study of initiating insulin therapy in type 2 diabetes. Pract Diab Int 2002;19:67-70
7. de Sonnaville JJJ, Snoek FJ, Colly LP, et al. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 1998;21:919-24
8. Wright A, Burden ACF, Paisey RB, et al.; for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
9. Turner RC, Cull CA, Frighi V, Holman RR; for the UK Prospective Diabetes Study group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
10. Halimi S, Raskin P, Liebl A, et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005; 27(Suppl B):S57-75
11. Shestakova M, Sharma SK, Almustafa A, et al. Transferring type 2 diabetes patients from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. [Epub ahead of print 13th Nov 2007]
12. Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). Horm Metab Res 2005;37:684-9
13. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006;8:58-66
14. Raskin P, Allen E, Hollander P, et al.; for the INITIATE study group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analog. Diabetes Care 2005;28:260-5
15. Schwartz S, Sievers R, Strange P, et al.; for the INS-2061 study team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003;26:2238-43
16. Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307-13
17. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab 2006;8:39-48
18. Raz I, Mouritzen U, Vaz J, et al. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003;25:3109-23
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
20. DCCT Research Group. The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-83
21. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
22. Davidson J, Vexiau P, Cucinotta D, et al. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther 2005;27(Supp B): S75-88
23. Skovlund SE, Peyrot M; on behalf of the DAWN International Advisory Panel. The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum 2005;18:136-42
24. Raccah D, Hanaire-Broutin H, Sert-Langeron C, et al. Insulin initiation in type 2 diabetic patients admitted in hospital in France and follow-up at 1 year: the IDAHO 2 study. Diabetes Metab 2006;32:244-50